taro-sunitinib capsule
taro pharmaceuticals inc - sunitinib (sunitinib malate) - capsule - 37.5mg - sunitinib (sunitinib malate) 37.5mg
taro-sunitinib capsule
taro pharmaceuticals inc - sunitinib (sunitinib malate) - capsule - 12.5mg - sunitinib (sunitinib malate) 12.5mg
taro-sunitinib capsule
taro pharmaceuticals inc - sunitinib (sunitinib malate) - capsule - 25mg - sunitinib (sunitinib malate) 25mg
taro-sunitinib capsule
taro pharmaceuticals inc - sunitinib (sunitinib malate) - capsule - 50mg - sunitinib (sunitinib malate) 50mg
auro-sunitinib capsule
auro pharma inc - sunitinib (sunitinib malate) - capsule - 12.5mg - sunitinib (sunitinib malate) 12.5mg
auro-sunitinib capsule
auro pharma inc - sunitinib (sunitinib malate) - capsule - 25mg - sunitinib (sunitinib malate) 25mg
auro-sunitinib capsule
auro pharma inc - sunitinib (sunitinib malate) - capsule - 37.5mg - sunitinib (sunitinib malate) 37.5mg
auro-sunitinib capsule
auro pharma inc - sunitinib (sunitinib malate) - capsule - 50mg - sunitinib (sunitinib malate) 50mg
sutent 12.5 mg
pfizer pharmaceuticals israel ltd - sunitinib as malate - capsules - sunitinib as malate 12.5 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.
sutent 25 mg
pfizer pharmaceuticals israel ltd - sunitinib as malate - capsules - sunitinib as malate 25 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.